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IgA nephropathy is the most common glomerular disease
worldwide, yet there is no international consensus for its
pathological or clinical classification. Here a new classification
for IgA nephropathy is presented by an international
consensus working group. The goal of this new system
was to identify specific pathological features that more
accurately predict risk of progression of renal disease in IgA
nephropathy, thus enabling both clinicians and pathologists
to improve individual patient prognostication. In a
retrospective analysis, sequential clinical data were obtained
on 265 adults and children with IgA nephropathy who were
followed for a median of 5 years. Renal biopsies from all
patients were scored by pathologists blinded to the clinical
data for pathological variables identified as reproducible by
an iterative process. Four of these variables: (1) the mesangial
hypercellularity score, (2) segmental glomerulosclerosis,
(3) endocapillary hypercellularity, and (4) tubular atrophy/
interstitial fibrosis were subsequently shown to have
independent value in predicting renal outcome. These specific
pathological features withstood rigorous statistical analysis
even after taking into account all clinical indicators available
at the time of biopsy as well as during follow-up. The features
have prognostic significance and we recommended they be
taken into account for predicting outcome independent of the
clinical features both at the time of presentation and during
follow-up. The value of crescents was not addressed due to
their low prevalence in the enrolled cohort.
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IgA nephropathy (IgAN) is the commonest glomerular
disease worldwide, yet there is no international consensus
for its pathological or clinical classification. Nephrologists
use clinical information to identify the risk of developing
progressive chronic kidney disease in individual patients with
IgAN. There is now extensive evidence that a number of
clinical features at presentation predict risk of progressive
chronic kidney disease. In published series, these consistently
include extent of proteinuria, hypertension, and excretory
renal function.1–5 Recent work also indicates the prognostic
importance of reduction in proteinuria during follow-up,
allowing continuing refinement of the prognostic informa-
tion given to an individual patient.6 Pathologists have
developed a number of classifications of IgAN over the last
25 years; some are semiquantitative,7–10 others are single-
grade classifications.11–15 Each of these classifications has
been developed from expert opinion, each has strengths and
limitations in predicting prognosis, and none has gained pre-
eminence. There is continuing debate whether pathological
features seen on renal biopsy contribute additional prognostic
information beyond that provided by clinical features.16
This lack of consensus on classifications based on
pathology has weakened a number of areas of investigation
into IgAN. It has contributed to slow progress in developing
a prognostic system with the sensitivity and specificity
to predict outcome for individual patients. It has reduced
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the capacity to make international comparisons between
different outcome studies, and it has limited opportunities to
refine the stratification of risk for the design of clinical
intervention trials. This is a major disadvantage in a slowly
progressive disease like IgAN where large studies of long
duration are needed to evaluate new interventions unless
patients with a high risk of progression can be better defined
early in the course of the disease.
In 2004, a proposal to develop a consensus clinico-
pathological classification came from the International IgA
Nephropathy Network—an informal network of nephro-
logists and scientists with representation from the majority
of nephrology research groups around the world active in the
field of IgAN (www.IgAN-world.org)—and members of the
Renal Pathology Society interested in IgAN. A questionnaire
among renal pathologists showed support for the develop-
ment of a consensus classification of IgAN provided it could
be shown to have real clinical utility. Therefore, representa-
tives of the International IgA Nephropathy Network and the
Renal Pathology Society established a working group to seek
agreement on an evidence-based clinicopathological con-
sensus classification for IgAN.17 From the beginning this was
designed as an international consensus aiming to involve
nephrologists and pathologists from as many parts of the
world as possible, including all areas where IgAN is known to
be of high prevalence. Eventually, the consensus group had
representation from 10 countries on four continents.
The goal of the new classification was to identify specific
pathological features that more accurately predict risk of
progression of renal disease in IgAN, which would enable
both clinicians and pathologists to improve individual
patient prognostication. It was recognized that such a
classification may also in the future facilitate the identifica-
tion of specific features that may predict response to
immunosuppression or other specific treatments, and refine
recruitment to clinical trials by their capacity to stratify
patients by their risk of progression.
The work was approached without preconceptions to test
objectively the predictive power of a wide range of pathological
features. The consensus work required unity of purpose and a
collaborative approach. Organizational challenges included the
development of tools allowing consistent data collection, and
the need to meet the varying requirements of institutional
review boards and ethics committees so that anonymized
pathological material and clinical data could be circulated
within and beyond its country of origin.
The overall approach used by the working group was the
following:
K Agreement on a clinical data set useful for outcome
studies in IgAN;
K Identification of centers willing to provide cases with
sufficient clinical data and biopsy material available for
review, including cohorts varying in age, and in
geographical and racial origin;
K Agreement on definitions and scoring of a wide range of
pathological features;
K Testing reproducibility between pathologists of scoring
these features; and
K Analysis of informative pathological features in the
context of clinical outcome to develop a classification.
By this rigor of approach, we aimed to gain the confidence
of clinicians and investigators worldwide, so that the new
classification will become the norm in routine clinical
practice and in future clinicopathological outcome reports
of IgAN.
The working group had two consensus meetings in 2005
and 2008, both held in Oxford, UK. It has, therefore, been
decided to call the product of our work, the Oxford
Classification of IgA Nephropathy.
RESULTS
Clinical data and adequate renal biopsy material from 265
patients with IgAN were collected from eight countries
on four continents. Five centers from Asia, six from Europe,
two from United States, one from South America, and
two multicenter networks (Canada and USA) participated in
the study (Table 1). The proportion of children was
similar in each continent (B30%).
Overall pathology findings
Pathology information was complete for each variable in all
265 cases. There were a median number of 18 glomeruli per
biopsy (interquartile range 8–24). Distributions of selected
pathology findings are shown in Figure 1. In all, 42 and 45%
of patients had endocapillary hypercellularity or crescents
(but the median numbers of glomeruli involved in each
affected patient were only 12 and 9%, respectively). Necrosis
Table 1 | Age and geographical origin of the study cohort of
265 cases of IgA nephropathy
Adults
Children (ageo18 years
at biopsy)
Total 265 206 59
Asia 48 14
China Beijing 12 2
Hong Kong 9 1
Nanjing 7 1
Japan Tokyo 19 1
Wakayama 1 9
Europe 73 21
France St Etienne 23 1
Italy Bari 23 1
Milano 16 3
Roma – 9
Torino 3 7
United Kingdom Glasgow 8 –
North America 82 24
Canada Toronto 32 0
United States Birmingham 12 1
Mayo Clinic 14 4
South West
Study Group
24 19
South America 3 0
Chile Santiago 3 0
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was seen in only six cases and glomerular basement
membrane duplication in 30 cases. The majority of patients
had no arterial or arteriolar lesions.
Reproducibility of pathology variables
The reproducibility of the various pathological lesions is
described in detail in the accompanying paper (Roberts
et al., The Oxford Classification of IgA Nephropathy
pathology definitions, correlations and reproducibility).18
Following refinement of the definitions, those pathological
lesions that continued to show poor reproducibility within the
working group were not incorporated into the final classifica-
tion, as even lower reproducibility could be expected in routine
practice without the advantage of the iterative processes of the
working group. These included the percentage of normal
glomeruli as well as the percentage of glomeruli showing
adhesions, glomerular basement membrane duplication, ne-
crosis, arteriolar lesions, and interstitial inflammation involving
non-fibrotic cortex. Reproducibility of scoring for adhesions
increased when combined with segmental sclerosis, suggesting
that different pathologists identified the same lesion as either
segmental sclerosis or an adhesion. For subsequent analysis,
segmental sclerosis and adhesions were summed.
Correlation between pathology variables
Details of the correlations between the different pathology
variables are presented in the accompanying paper (Roberts
et al.). For those variables that displayed considerable correla-
tion (r40.8), it was decided to include only one variable from
each group for further consideration based on reproducibility,
ease of identification, and susceptibility to sampling error.
The mesangial hypercellularity score was preferred to the
percentage of glomeruli showing severe mesangial hyper-
cellularity as it is more reproducible. A simplification of the
mesangial hypercellularity score to o50 or 450% showing
mesangial hypercellularity is described in the accompanying
paper. The percentage of glomeruli showing cellular and
fibrocellular crescents was preferred to the crescent score,
which required a complex calculation including scoring the
size of the crescents in each glomerulus. Interstitial fibrosis
combined with tubular atrophy was preferred to global
glomerulosclerosis, as its quantification is less susceptible to
error due to paucity of glomeruli or subcapsular sampling,
whichever was the higher value (interstitial fibrosis or tubular
atrophy) chosen. The highest arterial score for any size of
vessel was preferred to either the arcuate or interlobular
artery score as it was less susceptible to sampling error.
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Figure 1 | Frequency of pathological features in 265 renal biopsies. Percentage of patients with each pathological feature.
The six pathological features illustrated are those with sufficient reproducibility and frequency to merit evaluation for association with
clinical outcome. Glom, glomeruli.
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Therefore, the selected pathology variables used in the
subsequent analysis were the following:
mesangial hypercellularity score;
segmental glomerulosclerosis or adhesion;
endocapillary hypercellularity;
cellular only and cellular or fibrocellular crescents;
tubular atrophy/interstitial fibrosis; and
artery score.
Categorization of the selected pathology variables
The independent predictive value of the continuous glome-
rular variables could not be easily studied using multivariate
linear analysis in light of severely skewed distributions.
Therefore, receiver operating characteristic curves were drawn
for each variable to determine the optimal cutoffs predicting a
worse outcome (the most clinically relevant outcome was the
rate of renal function decline, which we needed to dichotomize
to perform this analysis). The optimal cutoff for the mesangial
hypercellularity score was 0.71. This number was approxi-
mated to 0.5 (without significant loss of sensitivity) to
facilitate scoring. Segmental glomerulosclerosis, endocapillary
hypercellularity, and extracapillary proliferation were categor-
ized as either present or absent as determined by receiver
operating characteristic curve. Tubular atrophy/interstitial
fibrosis was classified as absent (0%), mild (1–25%), moderate
(26–50%), or severe (450%), because this straightforward
reproducible classification is widely used in clinical practice.
Clinical features and outcome of the cohort
Clinical features at the time of biopsy and during follow-up are
shown in Table 2 and are typical of IgAN. At the time of renal
biopsy, the median age was 32 years (4–73 years), with
male predominance. The mean arterial pressure (MAP) was
98±18mmHg (63% of adult patients had blood pressure
above the value of 130/80mmHg and 31% were taking
antihypertensive medication). Nine children (15%) had
adjusted blood pressure 4130/80mmHg (MAP s.d. score
41) or were taking antihypertensive medication. The esti-
mated glomerular filtration rate (eGFR) values were evenly
distributed within stages 1, 2, and 3 of the Kidney Disease
Outcomes Quality Initiative (KDOQI) classification of chronic
kidney disease, although most children had stage 1 chronic
kidney disease (77%). Median proteinuria was 1.7 g per 24 h
(1.95 g per 24 h per 1.73m2 in children). Median follow-up was
5 years (range: 1–22 years, with 90% followed for more than 3
years). Twenty-nine percentage of the patients enrolled (47% of
children and 23% of adults) received immunosuppressive
therapy, consisting of variable dosages of corticosteroids with
additional immunosuppressive agents in only 9% of the cases.
Patients with segmental glomerulosclerosis, tubular atrophy/
interstitial fibrosis, and arterial lesions were more likely to have
been treated with renin-angiotensin system blockade (RAS)
blockade (angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker). Conversely, those with endocapillary
or extracapillary lesions received more immunosuppressive
treatment (Table 3). Fish oil was prescribed for 16% and statins
for 13% of the patients. No patient had a tonsillectomy during
the follow-up.
The mean rate of renal function decline was 3.5±
8.4ml/min per 1.73m2 per year (–3.7±6.6 in adults and
–2.7±1.05 in children, P40.1). The end point of 50%
decline in eGFR was reached in 22% of the cases and end-
stage renal disease (ESRD) was reached in 13%.
Correlations between pathological lesions and clinical
presentation at renal biopsy
This was a typical cohort of patients with IgAN as indicated
by the strong association observed between initial eGFR,
Table 2 | Clinical characteristics at the time of biopsy and follow-up in 265 patients with IgA nephropathy
At time of biopsy Follow-up
Age (years) 30 (4–73) Duration of follow-up (months) 69 (12–268)
Female 28%
Pediatric at time of biopsy (o18 years) 22%
Ethnicity (Caucasian/African/Asian/Other) 66, 3, 27, and 4%
BMI 25±6
MAP (mmHg) 98±17 MAP (mmHg) 95±10
Taking antihypertensive medication 31% No. of antihypertensive medications 0.9 (0–4.7)
Treated with RAS blockade 20% Treated with RAS blockade (ACEi and ARB) 74% (68 and 22%)
eGFR (ml/min per 1.73m2) 83±36 Rate of renal function decline (ml/min per 1.73m2 per year) 3.5±8.4
Stage 1, 2, 3 CKD (KDOQI) 36, 38, and 26% 50% Decline in renal function 22%
End-stage renal disease (o15ml/min per 1.73m2) 13%
Proteinuria (g/day) 1.7 (0.5–18.5) Proteinuria (g/day) 1.1 (0.1–9.3)
Previous macroscopic hematuria 34%
Previous immunosuppression 14% Immunosuppression 29%
Prednisone 29%
Other (cyclophosphamide) 9% (6%)
Previous use of fish oil 6%
Known previous tonsillectomy 6%
ACEi, angiotensin-converting inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; MAP, mean
arterial pressure; RAS, renin-angiotensin system.
Values are expressed as mean±s.d. or median (range). Calculation of MAP, eGFR, and proteinuria is detailed in the text.
eGFR, MAP, and proteinuria at onset were missing in 12% of cases. The median numbers of BP, GFR, and proteinuria measurements per patient were 7, 7, and 6, respectively.
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MAP, and proteinuria as well as follow-up MAP and
proteinuria and the outcomes measured (data not shown).
Mesangial score, segmental glomerulosclerosis, endocapillary
hypercellularity, and extracapillary proliferation were
strongly associated with proteinuria at the time of biopsy.
Segmental glomerulosclerosis was associated with reduced
eGFR and higher MAP at the time of biopsy. Tubular
atrophy/interstitial fibrosis was associated with a reduced
initial eGFR and higher initial MAP and proteinuria. Arterial
disease was strongly associated with initial blood pressure
and eGFR but had no relation with initial proteinuria
(Table 4).
Correlations between pathological lesions and outcome
By univariate analysis, the rate of renal function decline as
well as survival without ESRD or 50% reduction in initial
eGFR were significantly associated with a mesangial hyper-
cellularity score 40.5, presence of segmental glomerulo-
sclerosis, and tubular atrophy/interstitial fibrosis. As the
outcome in patients with absent tubular atrophy/interstitial
fibrosis was identical to the 1–25% group, we merged these
two categories to maximize statistical power (Table 5).
In the whole patient group, endocapillary and extra-
capillary proliferative lesions were not significantly predictive
of the rate of renal function decline, nor of survival from a
combined event. Patients with endocapillary hypercellularity
deteriorated at a rate of 3.8±10.6ml/min per 1.73m2 per
year compared with 3.3±6.4 in those without these lesions
(P40.1) and those with extracapillary proliferation deterio-
rated by 4.4±10.4ml/min per 1.73m2 per year compared
with 2.8±6.3 in those without (P40.1, with similar results
when addressing cellular crescents alone). However, there
was a significant interaction between endocapillary hyper-
cellularity and immunosuppression (see below). The rate of
renal function decline was almost identical in the different
artery score groups (data not shown).
Two models of multivariate analysis were calculated.
The first model was designed to address whether the
Table 3 | Therapy received during follow-up in relation to
pathological features
% RAS
blockade P-value
% Immuno-
suppression P-value
Mesangial hypercellularity score
p0.5 71 21
40.5 75 40.1 30 40.1
Segmental glomerulosclerosis
Absent 54 o0.001 28 40.1
Present 81 29
Endocapillary hypercellularity
Absent 76 17
Present 72 40.1 45 o0.001
Extracapillary hypercellularity
Absent 72 20 0.002
Present 78 40.1 39
Tubular atrophy/interstitial fibrosis
Absent 48 0.003 31 40.1
1–25% 76 28
26–50% 84 24
450% 85 50
Artery score
Absent 68 0.04 32 40.1
Mild 83 24
Moderate 86 19
Severe 75 50
Percentage of patients with each pathological feature receiving renin–angiotensin
system blockade or immunosuppressive therapy.
Table 4 | Correlations between pathological features and clinical features at the time of renal biopsy
MAP GFR Proteinuria
mmHg P-value ml/min per 1.73m2 P-value g/day P-value
Mesangial hypercellularity scorep0.5 100±18 40.1 84±28 40.1 1.4 (0.6–9.2) 0.001
Mesangial hypercellularity score 40.5 98±17 82±38 2.0 (0.5–18.5)
No endocapillary hypercellularity 101±19 0.008 76±31 0.001 1.5 (0.5–11.3) 0.01
Any endocapillary hypercellularity 95±15 92±40 2.0 (0.5–18.5)
No extracapillary proliferation 98±17 40.1 84±37 40.1 1.5 (0.5–18.5) 0.002
Any extracapillary proliferation 98±18 80±35 2.2 (0.5–12.0)
No segmental glomerulosclerosis 94±16 0.04 95±40 0.003 1.5 (0.5–7.2) 0.004
Any segmental glomerulosclerosis 100±18 79±34 1.9 (0.6–18.5)
Tubular atrophy and interstitial fibrosis
None (0%) 91±17 0.03 109±35 o0.001 1.5 (0.5–7.2) 0.03
Mild (1–25%) 99±18 86±35 1.7 (0.5–18.5)
Moderate (26–50%) 100±12 59±17 1.8 (0.6–7.5)
Severe (X51%) 105±24 46±27 3.0 (1.1–9.0)
Artery score
Absent 96±17 0.02 92±40 o0.001 1. 8 (0.5–18.5) 40.1
Mild 104±15 67±19 1.5 (0.6–4.6)
Moderate 101±20 70±25 1.6 (0.8–7.3)
Severe 102±7 72±33 1.7 (1.1–2.2)
GFR, glomerular filtration rate; MAP, mean arterial pressure.
Mean±s.d., median (range).
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biopsy findings predicted long-term outcome independently
of the initial assessment; it considered the pathology
variables in addition to the initial clinical data set (eGFR,
MAP and proteinuria). The second model was designed to
address which of the selected pathology variables were
independent predictors of outcome even when clinical
follow-up data were taken into account; this model included
pathology data, initial eGFR, and follow-up data (MAP and
proteinuria). Linear regression of rate of renal function
decline correlated with segmental glomerulosclerosis and
tubular atrophy/interstitial fibrosis in both models. The
mesangial hypercellularity score failed to attain independent
significance in both models. When the end points of ESRD or
50% reduction in eGFR was considered as the outcome, the
Cox regression showed for both models significant associa-
tions for mesangial hypercellularity score and tubular
atrophy/interstitial fibrosis, whereas the association for
segmental glomerulosclerosis failed to reach statistical
significance in both models. There was a marked reduction
in the mean hazard ratio from 1 (with mesangial hypercellu-
larity score40.5) to 0.11 (an 89% reduction) when the score
wasp0.5. There was a rapid escalation of the hazard ratio as
tubular atrophy/interstitial fibrosis increased: mean hazard
ratio 5 (when 26–50%) and 8.8 (when450%). The presence
of endocapillary and extracapillary lesions, and the severity
of arterial lesions were not statistically associated with
a decreased survival from a combined event (data not
shown).
There was a highly significant association by univariate
analysis between follow-up proteinuria and the mesangial
hypercellularity score, the presence of segmental glomerulo-
sclerosis or adhesions, and tubular atrophy/interstitial
fibrosis; their association with follow-up proteinuria per-
sisted even when adjusted for the initial proteinuria, GFR,
or MAP (data not shown).
Finally, odds ratios were also derived for a more rapid rate
of decline in renal function. Odds ratios were determined
after splitting the rate of renal function decline into two
halves and adjusting for both initial GFR and follow-up
blood pressure and proteinuria (Table 6).
Our analyses included 43 patients with less than 2 years of
observation, a relatively brief period for a condition as slowly
progressive as IgAN. To be sure this did not introduce
unforeseen bias, we recalculated all the multivariate models
Table 5 | Correlations between pathological features and outcomes: univariate and multivariate pathologic determinants
of slope
Rate of renal function decline (linear regression) Survival from renal failure or a 50% drop in GFR (Cox regression)
Univariate slope
Multivariatea
Univariate hazard ratio
Multivariatea
Model A Model B Model A Model B(ml/min per 1.73m2 per year)
b (s.d.) b (s.d.)
(95% CI)
Mesangial hypercellularity score
p0.5 0.5±3.3 2.2 (1.3) 0.8 (1.2) 0.06 (0.01–0.45) 0.07 (0.01–0.53) 0.11 (0.01–0.80)
40.5 4.2±9.0 1 1 1
Po0.001 P=0.10 P40.1 P=0.006 P=0.01 P=0.03
Segmental glomerulosclerosis
Absent 0.5±7.5 1 1 1
Present 4.4±8.4 3.6 (1.3) 2.5 (1.1) 3.1 (1.4–7.3) 1.8 (0.6–5.3) 2.5 (0.9–7.3)
P=0.001 P=0.005 P=0.03 P=0.009 P40.1 P=0.09
Tubular atrophy/interstitial fibrosisb
0–25% 2.5±7.6 5.2 (1.1) 3.7 (1.0) 1 1 1
26–50% 5.7±8.8 3.5 (1.9–6.5) 6.0 (2.7–13.9) 5.0 (2.3–11.1)
450% 11.1±12.6 15.5 (7.5–31.9) 17.3 (5.9–50.9) 8.8 (2.9–26.4)
Po0.001 Po0.001 Po0.001 Po0.001 Po0.001 Po0.001
CI, confidence interval; GFR, glomerular filtration rate; MAP, mean arterial pressure.
Endocapillary, extracapillary, and arterial lesions were not associated with the rate of renal function decline or survival from renal failure or a 50% drop in GFR (see text,
Correlations between pathological lesions and outcome).
aModel A: multivariate with three pathological features + initial GFR, MAP, proteinuria. Model B: multivariate with three pathological features + initial GFR and follow-up MAP
and proteinuria.
bOutcomes with 0% tubular atrophy/interstitial fibrosis were identical to 1–25% tubular atrophy/interstitial fibrosis, hence the two categories were combined to maximize
statistical power.
Table 6 | Examples of associations between pathological
variables and rapid rate of renal function decline
Odds ratio
95% confidence
intervals P-value
Tubular atrophy or interstitial fibrosis
0–25% 1 (Reference)
26–50% 3.0 1.3 7.4 0.01
51–100% 21.8 2.3 206.2 0.007
Segmental glomerulosclerosis present 2.8 1.2 6.2 0.01
Mesangial hypercellularity score40.5 2.1 0.9 4.7 0.08
GFR, glomerular filtration rate.
Decline defined by the worst half of the rate of renal function decline (slope 4
1.6ml/min per 1.73m2 per year). This model is adjusted for the initial GFR and the
follow-up blood pressure and proteinuria.
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using only patients with greater than 24 months of follow-up
(222 patients) and found the same statistically significant
pathology variables shown in Table 5 (data not shown).
Interaction of pathological features with therapy
In this retrospective study, it is possible therapy could
confound correlations between pathology and clinical out-
come. Therefore, the use of two major treatments, RAS
blockade and immunosuppression, was assessed in relation
to the selected pathological lesions (Table 3). Those with
endocapillary or extracapillary lesions were more likely to
receive immunosuppressive treatment. The relationship
between each pathology variable and the rate of renal
function decline was not influenced by immunosuppression
except for endocapillary lesions (P¼ 0.006). In patients who
received no immunosuppression, the rate of renal function
decline in those with endocapillary lesions was 5.4±
11.1ml/min per 1.73m2 per year, compared with
2.6±5.1ml/min per 1.73m2 per year in those without
endocapillary proliferation (P¼ 0.02). There was no such
difference in patients treated with immunosuppression,
providing indirect evidence that endocapillary lesions are
responsive to immunosuppressive therapy. Finally, we con-
firmed this significant interaction using survival from a
combined event for outcome and expressing immunosup-
pressive therapy as a time-dependant variable (time to start
of therapy) to address immortal time bias (data not shown).
We found no statistically significant interactions between
any of selected pathological features and RAS blockade.
Interaction of pathological features with age and ethnicity
There were marked differences in the pathology findings
between children and adults. Younger patients presented with
significantly less segmental glomerulosclerosis, tubular
atrophy/interstitial fibrosis, and fewer vascular lesions, but
had significantly more endocapillary lesions (data not shown).
However, the predictive value of each pathology variable on
the rate of renal function decline was not influenced by the age
at the time of biopsy (P40.1 for interaction term).
Finally, we studied whether ethnicity influenced the
predictive value of the biopsy. We only considered Caucasian
and Asian patients as there were too few subjects from other
racial groups for analysis. For each pathology variable, the
interaction term with ethnicity was not statistically signi-
ficant except for endocapillary lesions (P¼ 0.02); the rate
of renal function decline associated with this finding in
Asian subjects was significantly better compared with that in
Caucasians. However, Asian patients were significantly more
likely to receive immunosuppressive therapy during follow-
up (42% compared with 22% in Caucasians, P¼ 0.002) and,
in light of the interaction between endocapillary lesions
and immunosuppressive therapy outlined above, this finding
requires cautious interpretation.
In summary, our analysis shows that the following features
are independently predictive of clinical outcome: a mesangial
hypercellularity score 40.5, endocapillary hypercellularity,
segmental glomerulosclerosis, and the extent of tubular
atrophy/interstitial fibrosis.
Recommendations for renal biopsy reporting
These results would indicate that the renal biopsy report in
IgAN should specifically report on these four features,
for which brief definitions are shown in Table 7. We suggest
that these should be summarized and scored as shown in
(Table 8).
The biopsy report in IgAN should include a detailed
description of the features present on light microscopy,
immunohistochemistry, and electron microscopy. A diagnostic
statement giving the diagnosis and listing and
scoring of the four features above that are present in the
biopsy should then follow. Thus, an example of a diagnostic
summary would be as follows:
IgAN with mesangial proliferation, segmental sclerosis,
and 40% tubular atrophy/interstitial fibrosis (M1 E0 S1 T1).
In addition, to give a quantitative assessment of
glomerular inflammation and scarring, there should be
a summary of the total number of glomeruli and the
number with endocapillary proliferation, necrosis, cellular/
Table 7 | Definitions of pathological variables used in the classification of IgA nephropathy
Variable Definition Score
Mesangial hypercellularity o4 Mesangial cells/mesangial area=0 M0p0.5
4–5 Mesangial cells/mesangial area=1 M140.5a
6–7 Mesangial cells/mesangial area=2
48 Mesangial cells/mesangial area=3
The mesangial hypercellularity score is the mean score for all glomeruli
Segmental glomerulosclerosis Any amount of the tuft involved in sclerosis, but not involving the whole tuft
or the presence of an adhesion
S0 – absent
S1 – present
Endocapillary hypercellularity Hypercellularity due to increased number of cells within glomerular
capillary lumina causing narrowing of the lumina
E0 – absent
E1 – present
Tubular atrophy/interstitial fibrosis Percentage of cortical area involved by the tubular atrophy or
interstitial fibrosis, whichever is greater
0–25% – T0
26–50% – T1
450% – T2
aMesangial score should be assessed in periodic acid-Schiff-stained sections. If more than half the glomeruli have more than three cells in a mesangial area, this is categorized
as M1. Therefore, a formal mesangial cell count is not always necessary to derive the mesangial score.
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fibrocellular crescents, global glomerulosclerosis, and seg-
mental glomerulosclerosis.
As our data were derived from biopsies containing at
least eight glomeruli, we suggest that biopsies with fewer
glomeruli should be considered of uncertain value for
assessing prognosis.
DISCUSSION
Our objective was to develop a classification for IgAN
that would only consider pathological features that had
correlation to clinical outcome independent of the clinical
data, and would improve our current capacity to predict
the outcome of patients with this disease. None of the
previously established pathological classifications for IgAN
have achieved consensus in our community in part due to
the failure to show these correlations.7–9,11–13,19 One major
concern that applies to all pathology classifications is that
cross-sectional data, such as those obtained from a renal
biopsy specimen, are rarely as powerful a predictor of
outcome as longitudinal data obtained by a repeated clinical
assessment of patients; this is particularly true in a slowly
progressive disease such as IgAN. Such longitudinal data have
not been taken into account in the development of previous
pathological classifications of IgAN. In our study, the
independent value of specific pathology features was assessed
after the known relevant initial and follow-up clinical and
laboratory data were included in our models. Our objective
was to create a template that could integrate the identified
pathological parameters into routine renal pathology reports
and provide specific and new prognostic information for
both the clinician and the patient with IgAN.
The involvement of the International IgA Nephropathy
Network and the Renal Pathology Society enabled us to
acquire a study cohort that included a wide age spectrum and
was geographically and racially diverse. Creation of the
standardized platform for the evaluation of renal pathology
tissue was critical to our strategy and is reported in the asso-
ciated paper (Roberts et al.). This led to agreed definitions for
each pathological feature, which were refined by an iterative
assessment based on reproducibility, eliminating features that
could not be reconciled or were so infrequent as to be of little
use in a general classification of the disease. This was a
unique strategy never previously undertaken by a group of
renal pathologists, and led to a final pathology data set
suitable for routine clinical work comprising pathological
variables relatively common in IgAN that were easy to assess,
had a high degree of reproducibility, and independently
correlated with clinical outcome. The variables identified
were mesangial hypercellularity score, and the presence
or absence of segmental glomerulosclerosis, endocapillary
hypercellularity, and tubular atrophy/interstitial fibrosis.
We standardized the estimation of GFR, blood pressure,
and proteinuria.20–23 Standardization of eGFR was limited by
the use of different methods for measuring serum creatinine,
inevitably the case in such a retrospective multicenter
international study. Although this does introduce some
additional uncertainty about comparison of baseline eGFR
between individuals, accuracy of the calculation of slope of
eGFR is not affected, as it is based on serial measurements
of serum creatinine in the same institution using the
same method.
The majority of patients had significant proteinuria and
reasonable preservation of GFR at the time of biopsy, which
left us with the potential risk that the extremes of the
disorder, that is the most mild and most severe cases, would
not be represented. We expected that pathological lesions
indicative of progression would be rather infrequent in mild
cases, making them less informative and, therefore such cases
were best excluded from this study.24,25 At the other end of
the spectrum, rapidly progressive IgAN is rare, and is almost
always associated with abundant crescents.26,27 The require-
ment for study entry of at least 1 year of follow-up excluded
those most likely to have extensive crescent formation.
Although 45% of the study cohort had crescents, the median
number of glomeruli with crescents was only 9%, and no
case had more than 55% of glomeruli with crescents. We
recognize that the prognostic significance of crescents may
well be confirmed if validation cohorts include more rapidly
progressive cases, but based on the evidence obtained in this
cohort, we cannot justify their inclusion in this classification.
Similarly, we cannot make firm conclusions regarding the
significance of necrosis, which was rare in this series.
Reproducibility for the identification of necrosis was also
poor for the reasons discussed in the accompanying paper.
Despite these limitations, we remain confident we have
produced pathological criteria that could be applied to most
cases of IgAN.
The critical and unique value of the study is that we have
shown that these pathological features have a value inde-
pendent of the patient’s clinical parameters in predicting the
outcome in IgAN. We used three widely accepted clinical
outcomes in the models that assessed the independent
relevance of these variables. They include a surrogate
outcome—follow-up proteinuria; an outcome using a conti-
nuous variable—slope of eGFR; and renal survival—ESRD
Table 8 | Recommended elements in renal biopsy report for a
case of IgA nephropathy
Detailed description of the features present on
Light microscopy
Immunohistochemistry
Electron microscopy
Summary of four key pathological features
Mesangial scorep0.5 (M0) or 40.5 (M1)
Segmental glomerulosclerosis absent (S0) or present (S1)
Endocapillary hypercellularity absent (E0) or present (E1)
Tubular atrophy/interstitial fibrosisp25% (T0), 26–50% (T1), or
450% (T2)
Total number of glomeruli
Number of glomeruli with endocapillary hypercellularity, extracapillary
proliferation, global glomerulosclerosis, and segmental glomerulo-
sclerosis
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or 50% reduction from baseline of eGFR. The latter
combined survival estimate can be a misleading end point
in patients with an initial severe impairment of GFR, but the
observation that those reaching ESRD or a 50% reduction
from initial GFR parallel closely those with the most negative
slopes of eGFR and those with higher follow-up proteinuria
provides reassurance that these pathological parameters
correctly identify a poor prognostic cohort.6 Subsequent
multivariate analyses using these outcome variables con-
firmed that each of the selected pathological features
provided added value in estimating prognosis that was
independent of both the initial and follow-up clinical data.
The correlations between the pathological features and initial
clinical presentation were not unexpected, with some
exceptions discussed below, and helped to confirm that the
cohort was representative of the IgAN population. It is also
possible that immunosuppressive therapy is a significant
confounding factor. The presence of both endocapillary and
extracapillary lesions and crescents was strongly associated
with subsequent immunosuppressive treatment. Although we
cannot state that there was a cause-and-effect relationship,
this retrospective analysis does suggest that endocapillary
proliferation may be a lesion more responsive to immuno-
suppressive therapy, a suggestion supported by the markedly
higher rate of decline in renal function in those patients with
endocapillary proliferation who did not receive immuno-
suppressive treatment compared with those who did.
We obtained information on the use of angiotensin-
converting enzyme inhibitors and angiotensin receptor
blockers (Table 2), which indicated that they were prescribed
in 74% of the cohort at some time during follow-up. On
account of the retrospective nature of the study, reliable
information on duration of treatment or dosing could not be
obtained. It is, therefore, not possible to draw conclusions
with any confidence from this retrospective study about the
influence of renin–angiotensin blockade on outcomes.
The strongest support for the value of the mesangial
hypercellularity score, segmental glomerulosclerosis, and
extent of tubular atrophy/interstitial fibrosis as independent
markers of prognosis comes from the modeling in
Table 5.8,9,28–31 Whether the rate of decline in eGFR or renal
survival is used as the outcome, each of the factors remained
strongly positive by univariate analysis in the slope analysis
and by univariate hazard ratio in the renal survival model.
When the models were assessed by multivariate analysis with
initial eGFR, as well as when including follow-up blood
pressure and proteinuria, the selected pathology features
remained significant in one or both of the models. The odds
ratios determined after splitting the rate of renal function
decline into two halves and adjusting for both initial GFR
and follow-up blood pressure and proteinuria (Table 6)
further support the strong independent relevance of these
pathological features to outcome. The odds ratio for having a
faster rate of progression was highest with the greatest degree
of tubular atrophy/interstitial fibrosis and lowest with
mesangial hypercellularity. This is not unexpected given the
limitations of current therapy in modifying tubular atrophy/
interstitial fibrosis compared with the potential that anti-
hypertensive and/or immunosuppressive therapy may modify
mesangial hypercellularity. There were differences related
to pathology and clinical findings in our pediatric cohort.
Most were expected, that is there were fewer pathological
indicators of chronic disease.19 However, it is less obvious
why there were significantly more endocapillary proliferative
lesions in this age group; this has been previously reported
and it can be speculated that this represents a more vigorous
response to injury than in an older population. This might
explain the unexpected finding that endocapillary prolifera-
tion was associated with a higher eGFR and lower blood
pressure. However, an important observation is that, despite
these differences related to age, the predictive value of each of
the specific pathological variables was maintained across the
age spectrum. Regarding ancestry, there were no significant
differences in the predictive value of any pathology variables
comparing Caucasians and Asians in our cohort except that
the presence of endocapillary proliferation had less impact on
outcome in the Asian subjects. This exception may relate to
the higher percentage of Asians receiving immunosuppressive
therapy than Caucasians, possibly indicating an association
between treatment response and endocapillary proliferation,
rather than with ethnicity.
Previous classifications of glomerular disease (for
example, the World Health Organization/ISN classification
of lupus nephritis) have typically assigned four to six to
different classes or grades, with multiple pathological features
incorporated in each class. However, in our judgment, our
approach using individual specific pathological features is
easier to understand and apply, both at the individual patient
level and as part of a predictive algorithm. Each of the four
pathological variables that have been identified by our
rigorous methodology is independently associated with
outcome, and it is therefore recommended that routine
pathology reports in IgAN should be modified to specifically
report on these four pathological features without artificial
clustering into different ‘classes’ (Table 8). When offering a
prognosis to a patient with IgAN, the nephrologist should
now interpret the four pathology features, adding this to the
clinical features previously shown to be of prognostic value.
Table 9 gives examples of the way in which different
combinations of the pathological variables affected clinical
outcome in this cohort of patients. Although the risks are
cumulative, caution is required on the evidence available so
far; hazard ratios for each pathological variable cannot be
directly summed to quantify the risk of progression.
The limitations of this study must be recognized. It is a
retrospective observational review. In addition, the original
material was not uniformly collected at source and, by design,
comes from a wide variety of countries and centers, each with
their own laboratory methods of measuring renal function
parameters, that is serum creatinine and urine protein.
Despite these limitations, the specific pathological features
identified withstood rigorous statistical analysis confirming
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their value in predicting prognosis independent of both the
initial and follow-up laboratory data.
These results will need validation on an independent
data set that has been collected prospectively and in a
uniform manner. Validation may also lead to a further
refinement of these findings, for example whether the
number of glomeruli with evidence of endocapillary
hypercellularity is important, rather than simply the overall
presence or absence of this lesion in the biopsy. In
the meantime, however, it is our contention that these
pathological features can reliably and consistently be
evaluated, using the definitions provided and that both
pathologists and nephrologists will benefit by integration of
these features into their standard evaluations of the renal
tissue in patients with IgAN. In addition, this added value
appears to transcend both the age of the patient at biopsy and
their ancestry and is derived from a database that is
generalizable to most patients with IgAN.
MATERIALS AND METHODS
Pathology definitions
By an iterative process, pathological lesions were defined, lesions
with poor reproducibility among pathologists were excluded, and a
simplified set of pathology variables was agreed that was suitable for
further evaluation in IgAN. (This rigorous process is described in
more detail in the paper by Roberts et al.)
In brief, the final, simplified pathological variables were selected
based on reproducibility among pathologists, least susceptibility to
sampling error, ease of scoring in routine practice, and independent
correlation with outcome. Selection followed a pre-specified step-
by-step methodology, which is as follows:
a. Agreement between pathologists was first assessed and variables
were eliminated that showed poor reproducibility or were too
infrequently represented in the study cohort to be reliably
assessed.
b. Colinearity was measured between the remaining pathology
variables and identified different groups of variables with a high
correlation coefficient (rX0.8). Only one variable from each
group of highly correlated pathology variables was chosen.
c. Continuous pathology variables were then categorized to
facilitate scoring in the final proposed classification. Cutoffs for
each variable were determined by sensitivity analysis (using the
rate of renal function decline as the outcome).
d. Definitions were also modified where appropriate to reflect ease
of use and established conventions (for example, tubular atrophy
and interstitial fibrosis have usually been classified as absent,
mild, moderate, or severe).
e. Finally, the selected variables were tested in the study cohort for
independence from other pathological lesions and from known
clinical variables that impact on outcome at onset and during
follow-up.
Selection of patient cohorts for testing
Inclusion criteria. Cases were biopsy-proven IgAN (defined
by the predominant mesangial deposition of IgA) with an initial
eGFR X30ml/min per 1.73m2, and initial proteinuria 40.5 g per
24 h in adults and X0.5 g per 24 h per 1.73m2 in children.
It was necessary to ensure that selected cases included some in
whom there was significant deterioration in GFR over 5 years to
maximize the opportunity to identify discriminatory pathological
variables of independent importance in predicting outcome.
Patients who had received a range of different antihypertensive
agents and different immunosuppressive treatment schedules were
included.
Exclusion criteria. Cases with an initial eGFR o30ml/min
per 1.73m2 were excluded to minimize use of data from cases
with advanced disease likely to be beyond a ‘point of no return’;
Table 9 | (a) Combinations of glomerular features—examples of impact on deterioration in renal function; (b) combinations of
glomerular and tubulointerstitial features—examples of impact on deterioration in renal function
Glomerular lesions Criteria No. of patients Slope: ml/min per 1.73m2 per year
(a)
Minimal mesangial hypercellularity Without segmental sclerosis M0, S0, E0 13 0.7±2.5
With segmental sclerosis M0, S1, E0 22 1.5±2.7
Mesangial hypercellularity Without segmental sclerosis M1, S0, E0 31 2.2±4.3
With segmental sclerosis M1, S1, E0 88 4.7±7.6
Endocapillary proliferation Without segmental sclerosis M0/1, S0, E1 21 1.2±1.2
With segmental sclerosis M0/1, S1, E1 90 4.9±10.0
(b)
Glomerular lesions Tubular atrophy/interstitial fibrosis Criteria No. of patients Slope: ml/min per 1.73m2 per year
Minimal mesangial hypercellularity p25% M0, E0, T0 30 0.6±3.0
426% M0, E0, T1–2 5 1.0±1.2
Mesangial hypercellularity p25% M1, E0, T0 89 2.7±5.5
426% M1, E0, T1–2 30 7.9±9.1
Endocapillary proliferation p25% M0/1, E1, T0 88 3.0±1.9
426% M0/1, E1, T1–2 23 6.9±1.2
Note that certain combinations are very uncommon, for example, tubular atrophy/interstitial fibrosis (T1, T2) occurring with minimal glomerular lesions (M0, E0).
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it was recognized that this approach had the potential disadvantage
of excluding cases with the most acute course. Cases with o12
months of follow-up were excluded to minimize unreliability in
the estimation of the rate of renal function decline calculated
over a short time, recognizing this was likely to exclude the
most acute and rapidly progressive cases. Those with protein-
uria o0.5 g per 24 h were excluded to ensure the inclusion
of patients at risk of progression. Finally, those with secondary
causes of mesangial IgA deposits such as Henoch–Scho¨nlein purpura
or those with comorbid conditions such as diabetes mellitus were
excluded.
Clinical data set
Demographics were date of birth, gender, ethnicity, and age at the
time of biopsy. Children were subjects aged o18 years at biopsy.
Clinical parameters collected within 3 months of date of biopsy and
during follow-up included systolic and diastolic blood pressure,
weight, height, serum creatinine, and 24 h urine protein or urine
protein:creatinine ratio. To provide consistency between measure-
ments in adults and children, proteinuria was expressed in g per 24 h
per 1.73m2 in children and in g per 24 h in adults. Blood pressure
was adjusted for gender and age. Treatment modalities were
recorded including immunosuppressive agents, fish oil, statins,
tonsillectomy, and a number of antihypertensive medications
including angiotensin-converting enzyme inhibitor and angiotensin
receptor blockers. Data verification occurred by communication
between two of the lead authors (ST and RC) and contributing
centers.
Definitions
eGFR was estimated using the four-variable MDRD formula in
adults and the Schwartz formula in children (using the constant
0.55). ESRD was defined as GFRo15ml/min per 1.73m2. MAP was
defined as diastolic pressure plus a third of the pulse pressure. For
each child, the s.d. score for MAP was calculated19 and used to
normalize MAP to adult values. For each patient, an average MAP
and proteinuria were determined for each year of observation.
Follow-up MAP and proteinuria represent the average of these
values for MAP and proteinuria. Immunosuppressive treatment is
reported as intent to treat regardless of the type or duration of
therapy. RAS blockade indicates any exposure to either angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker,
or both.
Statistical methods
No available data could inform a calculation of the necessary
number of cases to allow confident exclusion of type 1 statistical
errors in subsequent analyses. A pragmatic recruitment goal was set
of 300 cases comprising 250 adults and 50 children. Centers were
asked to contribute between 5 and 50 cases with at least 5 years of
follow-up and a complete clinical data set.
Normally distributed variables were expressed as mean±s.d.
and were compared using Student’s t-test, one-way analysis
of variance, or Pearson test. Non-parametric variables were
expressed as median and range and compared using either
Mann–Whitney, Kruskal–Wallis, or Spearman test. Categorical
variables were expressed in percentages and compared using the
Pearson w2 test.
Reproducibility was assessed for each variable of the extended
pathology data set using intraclass correlation coefficient, a measure
of reproducibility applicable to multiple raters.32 By convention,
intraclass correlation coefficient of 0.40–0.59 is moderate inter-rater
reliability, 0.60–0.79 substantial, and 0.80 outstanding.33,34
Continuous pathological variables were categorized to facilitate the
applicability of the proposed classification. The relationship between
continuous pathological variables and the rate of renal function decline
(dichotomized in two groups using the median value) was depicted
with receiver operating characteristic curves, and the optimal cutoff
predicting a worse outcome was determined from these curves.
Three different clinical outcomes were studied to address the
predictive value of pathology variables, which are as follows: (a) the
rate of renal function decline (slope of eGFR); (b) survival from a
50% reduction in renal function, or ESRD; and (c) proteinuria
during follow-up (as a surrogate outcome measure). The rate of
renal function decline was determined by fitting a straight line
through available data for eGFR using the principle of least squares.
This was plotted and visually examined in each patient. Obvious
outliers were censored.
Univariate followed by multiple linear regression was used to
determine independent predictors of slope and follow-up protein-
uria. Different relevant multivariate models were tested obeying the
standard statistical rules. Only pathology variables significantly
associated with outcome were further considered. As the follow-up
proteinuria was skewed, its square root was used to respect the linear
regression assumptions. Slope was also categorized into two halves
to derive odds ratios of a more rapid rate of renal function decline
using logistic regression. Survival analysis using Cox regression was
performed to test the association between each pathological finding
and a combined event (50% reduction in renal function or ESRD, to
increase the rate of events and permit a valid multivariate analysis).
The same models described above were studied through multivariate
Cox regression.
Three pre-specified interactions were studied: whether age at
biopsy, ethnicity, and immunosuppressive treatment influenced the
relation between pathology and the rate of renal function decline
using general linear models.
All P-values were two-tailed and values less than 0.05 were
considered statistically significant. Confidence intervals included
95% of predicted values. Analyses were carried out using SPSS
software (version 11; SPSS Inc., Chicago, IL, USA).
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